The US Food and Drug Administration has conceded that its device approval processes need to be better protected against outside pressures after admitting to failings in the way its devices centre reviewed ReGen Biologics’s Menaflex device.
The failings are catalogued in the FDA’s preliminary report on the Menaflex case that has been published following an internal agency inquiry into the matter (see RAJ Devices online, September 28)...
Please login to read the full article.
